Suspended

Epigenetic Regulation of Excercise Induced Asthma

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Exercise challenge in the cold chamber (ECC)

+ mRNA profile

+ standard diagnostic

Diagnostic Test
Who is being recruted

Exercise-Induced Allergies+12

+ Dust Mite Allergy

+ Asthma

From 12 to 24 Years
See all eligibility criteria
How is the trial designed

Diagnostic Study

Interventional
Study Start: August 2021
See protocol details

Summary

Principal SponsorJohann Wolfgang Goethe University Hospital
Study ContactMelanie Dreßler, MDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: August 1, 2021

Actual date on which the first participant was enrolled.

Patients with known EIA are periodically reexamined by medical history, clinical examination, bodyplethysmography, spirometry, exhaled nitric oxide (eNO), skin prick test, methacholin challenge test and exercise-challenge in a cold-chamber at 2-4°C (ECC). Additionally the investigators gathers the questionnaires: Asthma Control Test (ACT) and Dyspnoe Index (DI). Besides these standard procedures the investigators want to investigate the micro-RNA profiles in two EIA subgroups: EIA with house-dust allergy (n = 24) and EIA without house-dust allergy (n = 24). Both groups are characterized by different eNO levels. The patients with EIA and house-dust allergy should have an eNO > 30 ppb, the patients with EIA without house-dust allergy an eNO < 20 ppb. The micro-RNA profiles of the both EIA subgroups will be compared the micro RNA profiles of 20 healthy controls . Therefore blood will be taken (for a complete blood count and micro RNA analysis) at three points of time: before ECC, directly after ECC and after 24 hours ± 4 hours after ECC.

Official TitleEpigenetic Regulation of Excercise Induced Asthma
Principal SponsorJohann Wolfgang Goethe University Hospital
Study ContactMelanie Dreßler, MDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

68 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Diagnostic Study

Diagnostic studies focus on improving how we detect or confirm a disease. They test new tools or techniques that could provide faster or more accurate diagnoses.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 12 to 24 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Exercise-Induced AllergiesDust Mite AllergyAsthmaAsthma, Exercise-InducedBronchial DiseasesHypersensitivityHypersensitivity, ImmediateImmune System DiseasesNose DiseasesOtorhinolaryngologic DiseasesRespiratory HypersensitivityRespiratory Tract DiseasesRhinitisRhinitis, Allergic, PerennialRhinitis, Allergic

Criteria

For EIA patients Inclusion Criteria: * written agreement * age \>=12 and \<= 24 * known exercise induced asthma * Group 1: skin prick test positiv house-dust allergy, eNO \> 30 ppb, MCT PD20 \< 0,1 mg * Group 2: skin prick test negative house-dust allergy, eNO \< 20 ppb, MCT PD20 \< 1 mg * lung function before ECC forced vital capacity (FVC) ≥ 75% and forced exspiratory pressure in one second (FEV1) ≥ 70% Exclusion Criteria: * age \< 12 und \> 24 years * lung function FVC \< 75% und FEV1\< 70% * inability to understand the range of the study * chronic asthma with systemic cortisone therapy * regular therapy with inhalative corticosteroids or leukotriene-antagonists \<14 days before visit 1 * intake of long acting beta-agonists (LABA) 48 h before examination * intake of short acting beta-agonists (SABA) 8 h before examination * acute severe infection (pneumonia) within the last 4 weeks * other chronic diseases or infections (HIV, Tbc) * pregnancy For healthy controls Inclusion Criteria: * written agreement * age \>=18 and \<= 24 Exclusion Criteria: * age \< 18 and \> 24 years * known asthma bronchiale or other chronic lung diseases * lung function FVC \< 90% and FEV1 \< 80% * allergic sensitization in skin prick test * eNO \> 30 ppb * inability to understand the range of the study * acute severe infection (pneumonia) within the last 4 weeks * other chronic diseases or infections (HIV, Tbc) * pregnancy

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Patients with EIA and house-dust mite allergy and an eNO \> 30 ppb

Group II

Patients with EIA without allergic sensitization and an eNO \< 20 ppb

Group III

Healthy controls without allergic sensitization or known asthma

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Universitätsklinikum Frankfurt

Frankfurt am Main, GermanyOpen Universitätsklinikum Frankfurt in Google Maps
SuspendedOne Study Center